IL-SESTEK
25.7.2016 15:58:35 CEST | Business Wire | Press release
SESTEK (Speech Enabled Software Technologies) was recently selected as the Best Technology Solution Provider at the Call Center Week Excellence Awards in Las Vegas, USA.
Annually, IQPC honors the most innovative contact center solutions based on creativity and execution across the full spectrum of call center functions. SESTEK was awarded for its products such as Voice Biometrics , Speech Analytics and Natural Dialog .
Professor Levent ARSLAN , CEO, dedicated the award to the SESTEK team and its customers by stating, “We are an ambitious group producing best-in-breed speech technology solutions. Our customers appreciate not only our technical perfectionism but also how we tailor the products exactly according to their needs. Unlike large-scale companies, we stay in touch with our customers throughout the whole process. The feedback from our customers is essential for us to improve our technologies systematically and deliver a consistent customer experience. Due to continuous communication, they decrease their costs but increase performance for a better customer experience. Our ability to adapt to the ever-changing needs of customers makes us a strong player in this industry and will help us grow further. Although we started small in 2000, SESTEK is rapidly growing in Chicago and Dubai by offering solutions in various languages, like Arabic and English. We appreciate the support of our current customers and look forward to finding solutions for the new customers and their needs.”
SESTEK (Speech Enabled Software Technologies) is a global provider of speech technology solutions, including Speech Analytics, Voice Biometrics, Text-to-Speech and Natural Dialog. SESTEK draws its strength from its patented technologies, pioneering role in academia-industry collaboration and growing clientele from various business areas. The performance and stability of SESTEK’s technologies and flexibility to tailor solutions to customers’ needs give the fast-growing company a unique advantage over its competitors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160725005748/en/
Contact:
SESTEK
Hilal Bakanay
hilal.bakanay@sestek.com
.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research21.10.2026 08:00:00 CEST | Press release
Okomera reaches a key milestone in its industrial rollout with the first commercial installation of its integrated platform, combining hardware, software and biology, in the laboratories of an international pharmaceutical group. Servier will use Okomera’s technology to evaluate new therapeutic approaches in oncology and immuno-oncology. Okomera, a TechBio company pioneering personalized cancer care through a proprietary technology platform combining tumor mini-avatars, microfluidics, and AI-powered imaging, today announced the signing of a commercial agreement with Servier, an independent international pharmaceutical group, to use its technology in the development of new cancer treatments. With more than 90% of oncology drug candidates never reaching the market, identifying early on the therapeutic approaches most likely to succeed is a critical challenge for the pharmaceutical industry. Okomera’s technology helps precisely reduce this attrition, by steering development toward candidat
Bureau Veritas: Double Digit Total Revenue Growth in the Third Quarter of 202621.10.2026 07:30:00 CEST | Press release
Organic revenue growth sequential improvement;2026 outlook confirmed Bureau Veritas (BOURSE:BVI): The execution of LEAP | 28 has transformed Bureau Veritas into a more focused, faster-growing and higher-performing multi-specialist company. Its Product Line-centric operating model combines the Company’s global scale and resilience with clear priorities, stronger accountability and deep specialist expertise. This creates a more repeatable growth model, enabling faster execution, stronger capabilities and higher conversion of growth into profitability. Q3 2026 Key figures1 › New reporting structure effective July 1st, 2026, comprising four divisions: Industrials & Commodities, Buildings & Infrastructure, Business Assurance, and Product Testing & Services, excluding the planned for exit businesses of Oil & Petrochemicals and Coal Testing and Inspection, and “Government Services”; › Revenue of EUR 1,569.7 million, up 10.1% year-on-year and up 6.2% organically; • Positive scope effect of 1.8
AI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study Finds21.10.2026 07:00:00 CEST | Press release
Third annual edition of The CEO Response finds leaders prioritizing AI and business alliances as demands on CEO leadership grow Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty, according to The CEO Response, Egon Zehnder's third annual study of 843 global chief executives. Nearly half of CEOs (48%) consider the adoption and impact of AI an extremely critical challenge, up from 37% in 2025. Geopolitical instability (44%) and economic uncertainty (40%) follow, while 62% expect geopolitical disruption to increase over the next 12 months. These challenges are shaping where CEOs are focusing their efforts. Half (50%) identify AI investment among the three most important changes they're making to their organizations, followed by innovation (48%) and improving their cost base (41%). By comparison, 29% selected upskilling and talent development as a top priority. “CEOs can invest in AI much fas
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership21.10.2026 07:00:00 CEST | Press release
Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8 With 30 years of innovation, Restylane continues to evolve through the development of new technologies and expanded clinical indications, with data to be presented from four studies across the chin, jawline, temples, and lower face Several Meet-the-Expert sessions and a symposium on the AART™ of Body, which highlights new expanded indications for Sculptra in the gluteal area, posterior thighs, and décolletage, follows Sculptra’s recent approval for use on the body in the United Arab Emirates (UAE)9 Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company
Sihoo præsenterer næste generation af ergonomiske kontorløsninger på ORGATEC 202620.10.2026 20:12:00 CEST | Pressemeddelelse
Med ORGATEC 2026 lige om hjørnet vil Sihoo, specialist i ergonomiske sidde løsninger, præsentere sine næste generations løsninger til arbejdspladsen i hal 8.1, stand A-060 og B-061. I tråd med messens tema, »Fra rum til relationer: design af rum i en verden i konstant forandring«, vil Sihoo demonstrere, hvordan adaptivt ergonomisk design understøtter skiftende siddestillinger og nye behov på moderne arbejdspladser. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261020048673/da/ Sihoo på ORGATEC 2026 i Köln En oplevelseszone baseret på forskellige arbejdsscenarier Sihoos stand har et åbent layout, hvor en orange-hvid farvepalet kombineres med loftskonstruktioner i flere niveauer, halvgennemsigtige skillevægge og integreret belysning. Arbejdsstationer med højdejusterbare skriveborde og skærme samt siddeområder til samarbejde genskaber velkendte kontormiljøer og viser, hvordan ergonomiske stole passer ind på moderne arbejdspl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom